NRSNW — NEUROSENSE THERAPEUTICS LTD
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 3 SEC-registered investment managers reported holding NRSNW (NEUROSENSE THERAPEUTICS LTD) in their latest 13F filings, with a combined reported value of $7.19K across 159.85K shares. That is -2.9% by share count (-4.80K shares) versus the previous quarter, while reported value moved -30.7%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of NEUROSENSE THERAPEUTICS LTD (NRSNW) include Hudson Bay Capital Management LP, Citadel Advisors, Empery Asset Management, LP, ranked by reported 13F value among the 7 institutional holders on this page.
NRSNW is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 3 | 159.85K | $7.19K | -2.9% |
| Q2 2026 | 3 | 164.65K | $10.37K | -0.2% |
| Q1 2026 | 3 | 164.95K | $32.82K | +0.0% |
| Q4 2025 | 3 | 164.95K | $56.70K | -0.6% |
| Q3 2025 | 2 | 64.97K | $24.60K | -12.9% |
| Q2 2025 | 1 | 1.47K | $932 | -48.3% |
| Q1 2025 | 2 | 12.84K | $2.63K | -28.8% |
| Q4 2024 | 3 | 40.74K | $14.97K | -10.8% |
Over the 8 quarters shown, institutional share counts increased 292% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q2 2025 (-48.3%).
Top Institutional Holders (Q3 2026) — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 95.50K | $4.30K | 0.00% | Reduce | |
| 63.19K | $2.84K | 0.00% | Hold | |
| 1.16K | $52 | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 100.40K | $6.33K | 0.01% | Hold | |
| 63.09K | $3.97K | 0.00% | Hold | |
| 1.16K | $73 | 0.00% | Hold |
Q1 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 100.40K | $20.08K | 0.02% | Hold | |
| 63.38K | $12.68K | 0.00% | Hold | |
| 1.16K | $64 | 0.00% | Hold |
Q4 2025 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 100.40K | $36.15K | 0.03% | New | |
| 63.38K | $20.26K | 0.00% | Hold | |
| 1.16K | $291 | 0.00% | Reduce |
Q3 2025 — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 63.69K | $24.20K | 0.00% | New | |
| 1.28K | $397 | 0.00% | Reduce |
Q2 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 1.47K | $932 | 0.00% | Reduce |
New Positions (Q3 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 7 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP | 95.50K | 100.40K | 100.40K | 100.40K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Clear Street Group Inc. | 63.19K | 63.09K | 63.38K | 63.38K | 63.69K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 1.16K | 1.16K | 1.16K | 1.16K | 1.28K | 1.47K | 2.84K | 94 | 200 | 605 | — | — | 3.80K | — | — | 798 | 1.96K | 4.49K |
| Hudson Bay Capital Management LP | — | — | — | — | — | — | — | — | — | — | 86.75K | 86.75K | 86.75K | — | — | — | — | — |
| Citadel Advisors | — | — | — | — | — | — | — | 22.71K | 25.27K | 29.46K | 48.14K | — | 11.59K | 37.93K | 32.61K | — | — | — |
| Warberg Asset Management LLC | — | — | — | — | — | — | 10.00K | 17.94K | 20.20K | 32.01K | 41.41K | 63.50K | 76.11K | — | — | — | — | — |
| Bank of America Corp | — | — | — | — | — | — | — | — | — | — | — | — | 200 | 100 | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold NRSNW?
As of 2026-Q3, 3 institutional funds reported holding NRSNW (NEUROSENSE THERAPEUTICS LTD) in SEC 13F filings, with a combined reported value of $7.19K.
How many shares of NRSNW do institutions own?
13F filers reported 159.85K shares of NRSNW, worth $7.19K in aggregate at the end of 2026-Q3.
Is institutional ownership of NRSNW rising or falling?
Share counts moved -2.9% versus the prior quarter — distribution.
Who are the top institutional holders of NRSNW?
The largest 13F holders are Hudson Bay Capital Management LP, Citadel Advisors, Empery Asset Management, LP, Clear Street Group Inc., Warberg Asset Management LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of NEUROSENSE THERAPEUTICS LTD?
The major shareholders of NEUROSENSE THERAPEUTICS LTD (NRSNW) by reported 13F value are Hudson Bay Capital Management LP, Citadel Advisors, Empery Asset Management, LP, Clear Street Group Inc., Warberg Asset Management LLC, among 7 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.